ClinTec International, a global CRO with a large presence in the Middle East and Africa, has expanded its operations into Malawi, appointing its first highly experienced clinical research associates.
A large pharmaceutical company with sales exceeding $50 billion has selected ClinTec as its preferred partner for vaccine development in Africa and Asia, further enhancing ClinTec’s growing presence in the emerging markets of Africa, Asia and the Middle East. The global vaccines market has an estimated value of $33.8 billion.
“I am pleased with our continued expansion in Africa and see huge potential for the company in conducting large scale vaccine trials,” said Dr. Rabinder Buttar. “Despite the challenging economic conditions through which many of our clients are restructuring their organizations, ClinTec continues to grow and win major new business from pharma companies.”
Clin Tec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, while complying in full with international clinical research guidelines. The company is also in the process of recruiting more personnel with vaccine research experience to join its established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.
Buttar added, “As the pharmaceutical industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs.”